Key Points
- William Lewis, Insmed's CEO, sold 10,699 shares on April 16 at an average price of $143.97 for about $1.54M, leaving him with 301,185 shares (a 3.43% reduction); the sale was executed under a pre-arranged Rule 10b5-1 plan.
- Lewis has repeatedly sold similar blocks of stock across January–April (multiple sales of 10,699 shares plus other tranches), indicating an ongoing, planned selling schedule rather than a one-off transaction.
- Insmed recently missed quarterly EPS estimates (reported -$1.54 vs. -$1.07 expected) despite revenue rising 152.6% year-over-year to $263.8M; the company has a market cap of about $31.2B and an average analyst rating of Buy with a $213.23 price target.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the firm's stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03. Following the sale, the chief executive officer owned 301,185 shares of the company's stock, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
William Lewis also recently made the following trade(s):
- On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $163.22, for a total value of $1,746,290.78.
- On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48.
- On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97.
- On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total value of $1,615,228.03.
- On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84.
- On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total value of $470,427.06.
- On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07.
Insmed Trading Up 1.2%
NASDAQ:INSM opened at $144.48 on Friday. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. The business's 50 day moving average is $149.95 and its two-hundred day moving average is $167.31. Insmed, Inc. has a 52 week low of $63.81 and a 52 week high of $212.75. The company has a market cap of $31.19 billion, a PE ratio of -22.54 and a beta of 1.10.
Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same period in the prior year, the business earned ($1.32) EPS. The company's quarterly revenue was up 152.6% on a year-over-year basis. On average, analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. Wells Fargo & Company reduced their target price on Insmed from $208.00 to $175.00 and set an "overweight" rating on the stock in a report on Monday, March 23rd. Bank of America increased their target price on Insmed from $211.00 to $213.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Stifel Nicolaus increased their target price on Insmed from $205.00 to $208.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Roth Mkm reissued a "buy" rating and issued a $212.00 price target on shares of Insmed in a report on Friday. Finally, Leerink Partners raised their price target on Insmed from $210.00 to $215.00 and gave the stock an "outperform" rating in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $213.23.
Read Our Latest Stock Analysis on Insmed
Institutional Trading of Insmed
Hedge funds have recently added to or reduced their stakes in the business. CoreCap Advisors LLC bought a new stake in Insmed during the 4th quarter valued at $27,000. Reflection Asset Management bought a new stake in Insmed during the 4th quarter valued at $30,000. GraniteShares Advisors LLC bought a new stake in Insmed during the 4th quarter valued at $30,000. CIBC Private Wealth Group LLC raised its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 53 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in Insmed during the 4th quarter valued at $32,000.
About Insmed
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
